Neurogene Inc. (NASDAQ: NGNE) shares climbed 30% in after-hours trading Thursday following a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to NGN-401, the company's investigational gene therapy targeting Rett syndrome.

Clinical Data Drives Regulatory Success

Compelling interim efficacy and safety data supported the FDA’s decision. Results from the Phase 1/2 trial, with a data cutoff of October 30, 2025, demonstrated clinically meaningful and durable functional improvements. Furthermore, the data indicated that patients achieved continued skill acquisition over time across multiple domains of Rett syndrome.

Mechanism and Delivery

Neurogene engineered NGN-401 as a one-time treatment designed to address the root cause of the disorder. It delivers the full-length human MECP2 gene using the company’s proprietary EXACT transgene regulation technology. To ensure maximum efficacy, physicians administer the therapy through intracerebroventricular delivery, allowing the treatment to directly target the brain and nervous system.

Future Milestones and Trial Progress

Currently, the company is evaluating NGN-401 within the Embolden registrational clinical trial. Neurogene projects it will complete dosing for this trial in the second quarter of 2026. Following this milestone, the company plans to present additional interim Phase 1/2 clinical data in mid-2026.

Implications of Breakthrough Therapy Status

This designation serves to expedite the development and review of medicines intended for serious conditions. To qualify, a drug must show preliminary clinical evidence indicating substantial improvement over available therapies. Consequently, Neurogene secures several strategic advantages, including eligibility for Priority Review and the option to submit sections of the Biologics License Application on a rolling basis. The designation also guarantees FDA organizational commitment to identifying an efficient route to approval.

This achievement complements NGN-401’s existing regulatory profile. The FDA previously granted the therapy Regenerative Medicine Advanced Therapy (RMAT) and Rare Pediatric Disease designations. Additionally, the agency selected NGN-401 for its Support for Clinical Trials Advancing Rare Disease Therapeutics Pilot Program.

To find out more information on Neurogene Inc. please visit www.neurogene.com .

The post Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy appeared first on PRISM MarketView.

COMTEX_474333812/2927/2026-02-27T09:00:45